Table 2.

Major societal recommendations regarding using biomarkers to guide anticoagulation

Biomarkers to guide anticoagulation
CDC	Insufficient data to recommend for or against using hematologic and coagulation parameters to guide management decisions.
ISTH-IG	Not mentioned
ACF	Biomarker thresholds such as D-dimer for guiding anticoagulation management should not be done outside the setting of a clinical trial.
ASH	No particular change to regimen recommended for patients with lupus like inhibitors. TEG and ROTEM should not be used routinely to guide management.
ACCP	Not mentioned
SSC-ISTH	D-dimer levels should not be used solely to guide anticoagulation regimens.
ACC	Further investigation is required to determine the role of antiphospholipid antibodies in pathophysiology of COVID-19-associated thrombosis. D-dimer > 2 times the upper limit may suggest that patient is at high risk for VTE and consideration of extended prophylaxis (up to 45 days) in patients at low risk of bleeding.

Abbreviations: COVID-19 coronavirus disease 2019, ROTEM rotational thromboelastometry, TEG thromboelastography, VTE venous thromboembolism